Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
By Virginia A. Moyer. Annals of Internal Medicine, 2012
2,107 citations recorded by the source corpus.
DESCRIPTION Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. METHODS The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. RECOMMENDATION The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).This recommendation applies to men in the general U.S. population, regardless of age. This recommendation does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer; the use of the PSA test for this indication is outside the scope of the USPSTF.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/7a1f2cc5cb7a29a4d53f3a0ba9053708d5c33504
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Endocrine Treatment of Gender‐Dysphoric/Gender‐Incongruent Persons: An Endocrine Society* Clinical Practice Guideline (2017, neutral): “Thus, it may be reasonable for trans-gender females who transitioned after age 20 years to have annual screening digital rectal examinations after age 50 years and prostate-specific antigen tests consistent with U.S. Preventive Services Task Force Guidelines (215).”
- Cancer statistics, 2023 (2023, background): “5,37 42 and more targeted screening for clinically significant tumors using molecular markers and magnetic resonance imaging ‐ targeted biopsy.”